Headache

OnabotulinumtoxinA Therapy for Headache

Outcomes Following OnabotulinumtoxinA Treatment (N = 1455)

2023

HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System, GAD-7 = Generalized Anxiety Disorder Questionnaire

​

In 2022-2023, 1455 headache patients who were treated with onabotulinumtoxinA were reviewed. Following treatment, 87.2% had improved or stable headache impact,¹ PROMIS Global Health,² depression ,³ and anxiety scores.⁴

References
  1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-380.
  2. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-880.
  3. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004 Dec;42(12):1194-1201.
  4. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Harter M, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401.